108 related articles for article (PubMed ID: 25789534)
1. Determination of True ERBB2 Gene Amplification in Breast Cancer by Quantitative PCR Using a Reference and a Novel Control Gene.
Chamizo C; Rojo F; Madoz-Gúrpide J
Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):179-87. PubMed ID: 25789534
[TBL] [Abstract][Full Text] [Related]
2. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
3. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
[TBL] [Abstract][Full Text] [Related]
5. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
Mrhalová M; Kodet R; Kalinová M; Hilská I
Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
[TBL] [Abstract][Full Text] [Related]
6. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
7. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
[TBL] [Abstract][Full Text] [Related]
8. Detection of HER2 status in breast cancer: comparison of current methods with MLPA and real-time RT-PCR.
Pazhoomand R; Keyhani E; Banan M; Najmabadi H; Khodadadi F; Iraniparast A; Feiz F; Majidzadeh K; Bahman I; Moghadam FA; Sobhani AM; Muhammadnejad A; Abedini SS; Behjati F
Asian Pac J Cancer Prev; 2013; 14(12):7621-8. PubMed ID: 24460343
[TBL] [Abstract][Full Text] [Related]
9. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
10. Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.
Zoppoli G; Garuti A; Cirmena G; di Cantogno LV; Botta C; Gallo M; Ferraioli D; Carminati E; Baccini P; Curto M; Fregatti P; Isnaldi E; Lia M; Murialdo R; Friedman D; Sapino A; Ballestrero A
J Transl Med; 2017 May; 15(1):91. PubMed ID: 28460632
[TBL] [Abstract][Full Text] [Related]
11. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
13. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
[TBL] [Abstract][Full Text] [Related]
14. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
15. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
Moelans CB; de Weger RA; van Diest PJ
Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
[TBL] [Abstract][Full Text] [Related]
16. An alternative and reliable real-time quantitative PCR method to determine HER2/neu amplification in breast cancer.
Egervari K; Toth J; Nemes Z; Szollosi Z
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):247-54. PubMed ID: 19098680
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Baehner FL; Achacoso N; Maddala T; Shak S; Quesenberry CP; Goldstein LC; Gown AM; Habel LA
J Clin Oncol; 2010 Oct; 28(28):4300-6. PubMed ID: 20697093
[TBL] [Abstract][Full Text] [Related]
18. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry.
Capizzi E; Gruppioni E; Grigioni AD; Gabusi E; Grassigli A; Grigioni WF; Fiorentino M
Diagn Mol Pathol; 2008 Dec; 17(4):220-6. PubMed ID: 18382352
[TBL] [Abstract][Full Text] [Related]
19. Comparative multi-methodological measurement of ERBB2 status in breast cancer.
Ginestier C; Charafe-Jauffret E; Penault-Llorca F; Geneix J; Adélaïde J; Chaffanet M; Mozziconacci MJ; Hassoun J; Viens P; Birnbaum D; Jacquemier J
J Pathol; 2004 Mar; 202(3):286-98. PubMed ID: 14991893
[TBL] [Abstract][Full Text] [Related]
20. Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens.
Susini T; Bussani C; Marini G; Nori J; Olivieri S; Molino C; Bianchi S; Vezzosi V; Paglierani M; Giachi M; Borrani E; Scarselli G
Gynecol Oncol; 2010 Feb; 116(2):234-9. PubMed ID: 19919879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
